GlassScriptPhysician profile
Mark S Zaremba
NPI 1023094273
$3,336.10
in general payments reported to CMS, 2019-2025
22 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $444 · 2021: $713 · 2022: $261 · 2023: $427 · 2024: $510 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.99 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $720.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $521.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $496.08 | 2020-2025 | Farxiga |
| Novo Nordisk INC | $415.12 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $334.89 | 2019-2023 | Livalo, Seglentis |
| Amgen INC. | $155.19 | 2019-2024 | Repatha |
| Abiomed | $149.80 | 2023-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.70 | 2021-2024 | Jardiance |
| Arbor Pharmaceuticals, INC. | $74.32 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $68.81 | 2019-2021 | |
| Amarin Pharma, INC. | $42.50 | 2020 | |
| Edwards Lifesciences Corporation | $39.08 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Azurity Pharmaceuticals, INC. | $30.98 | 2025 | Edarbi |
| Eisai INC. | $24.86 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.12 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.04 | 2020 | |
| Pfizer INC. | $20.89 | 2023 | |
| Abbvie INC. | $19.81 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.42 | 2021 | |
| Horizon Therapeutics Plc | $18.49 | 2020 | |
| Exact Sciences Corporation | $17.28 | 2025 | The Cologuard Plus Collection Kit |
| Philips North America LLC | $15.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Zaremba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.